The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
EFFECTOR THERAPEUTICS INC COM 28202V108   5,594,133 6,822,114 SH   SOLE   6,822,114 0 0
DESIGN THERAPEUTICS INC COM 25056L103   41,116,799 6,526,476 SH   SOLE   6,526,476 0 0
ARCELLX INC COMMON STOCK 03940C100   124,792,441 3,946,630 SH   SOLE   3,946,630 0 0
NKARTA INC COM 65487U108   2,919,999 1,333,333 SH   SOLE   1,333,333 0 0
ARS PHARMACEUTICALS INC COM 82835W108   26,886,450 4,012,903 SH   SOLE   4,012,903 0 0
MINERALYS THERAPEUTICS INC COM 603170101   30,597,930 1,794,600 SH   SOLE   1,794,600 0 0